NASDAQ · Biotechnology

Lumos Pharma, Inc. (LUMO) Stock

$4.34 +0.00% NASDAQ: LUMO Healthcare

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions.

Valuation

MetricValue
Price$4.34
Market Cap$37.54M
P/E Ratio-1.04
P/B Ratio1.29
P/S Ratio18.30
EPS (TTM)$-4.18
52-Week High$4.58
52-Week Low$1.37
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-78.34%
ROA-83.75%
ROCE-108.94%
Gross Margin100.00%
Operating Margin-1850.00%
Net Margin-1700.00%
Debt/Equity0.02
Current Ratio5.69

Annual Financials (USD)

Metric20192020202120222023
Revenue$1.0M$0$0$2.0M$2.0M
Operating Profit$-45.0M$-26.0M$-31.0M$-32.0M$-37.0M
Net Profit$-43.0M$-6.0M$-30.0M$-31.0M$-34.0M
EPS$-10.39$-0.84$-3.65$-3.71$-4.18
Op Margin-4822.0%-15656.5%-13629.1%-2103.7%-1785.2%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$97.0M$129.0M$100.0M$72.0M$41.0M
Total Liabilities$18.0M$12.0M$11.0M$13.0M$13.0M
Cash$91.0M$99.0M$95.0M$56.0M$35.0M
Borrowings$1.0M$0$1.0M$0$1.0M

Latest News

Is McCormick’s (MKC) Black Currant Menu Push a Subtle Bet on Brand-Led Growth? Simply Wall St. · Aug 8, 2026 7 Reasons Pershing Square (PS) Looks Pricey After Ackman Spotlighted AI Holdings Simply Wall St. · Aug 8, 2026 Will AI-Driven Advanced Packaging and Record Q2 Results Reshape Nova’s (NVMI) Investment Narrative? Simply Wall St. · Aug 8, 2026 Sharplink (SBET) Looks Pricey Following Earnings That Put Growth And Losses In Focus Simply Wall St. · Aug 8, 2026 Is Rolls-Royce Holdings (LSE:RR.) Fully Valued After Buybacks, Half Year Results And A Dividend Increase? Simply Wall St. · Aug 8, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-30.0M$-23.0M$-30.0M$-27.0M$-31.0M
Investing Cash Flow$0$117.0M$26.0M$-23.0M$11.0M
Financing Cash Flow$0$0$0$-1.0M$-1.0M
Net Cash Flow$-30.0M$94.0M$-4.0M$-39.0M$-21.0M
Free Cash Flow$-30.0M$-23.0M$-30.0M$-27.0M$-31.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA-0.08
FCF Yield-82.84%
Quick Ratio5.69
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CERCCerecor Inc. $2.93 -1.68% -0.53 $38.63M 0.00%
EYENEyenovia, Inc. $7.56 +3.99% -1.14 $38.59M 0.00%
GRCE $2.37 +3.04% -2.26 $38.57M 0.00%
IRDOpus Genetics, Inc. $3.32 +7.63% -2.35 $273.71M 0.00%
LIANYLianBio $0.07 -12.50% 1.56 $7.64M 6.14%

About Lumos Pharma, Inc.

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.

Lumos Pharma, Inc. is headquartered in US.

Lumos Pharma, Inc. (LUMO) stock trades at $4.34 with a market capitalization of $37.54M. The stock is valued at a price-to-earnings (P/E) ratio of -1.04, price-to-book of 1.29, price-to-sales of 18.30. Over the past 52 weeks the stock has ranged between $1.37 and $4.58, and currently trades 5.2% below its 52-week high.

On profitability, Lumos Pharma, Inc. generates a return on equity (ROE) of -78.34%, return on capital employed of -108.94%, an operating margin of -1850.00%, a net profit margin of -1700.00%.

Official website: www.lumos-pharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides